Press Releases
ARBIOS SYSTEMS PRESENTATION AT RODMAN & RENSHAW TECHVEST 3rd ANNUAL GLOBAL HEALTHCARE CONFERENCE TO BE WEBCAST LIVE
WALTHAM, MASSACHUSETTS – May 8, 2006 -- Arbios Systems, Inc. (OTC: ABOS) a medical device and cell-based therapy company developing proprietary liver support products to enhance the survival of the millions of patients each year who experience, or who are at risk of, life threatening episodes of liver failure, today announced that Walter Ogier, President and Chief Executive Officer, will be presenting a summary of the Company and an update of the SEPET™ Liver Assist Device first-in-man feasibility clinical trial at the Rodman & Renshaw Techvest 3rd Annual Global Healthcare Conference on Monday, May 15, 2006 in Monte Carlo, Monaco at 5:05pm local time (11:05am Eastern Time).
The presentation will be webcast live and can be accessed at http://wsw.com/webcast/rrshq8/abos or through the Company’s website at http://www.arbios.com. An archived recording of the presentation will be available for 90 days following.
Arbios Systems, Inc. is a publicly traded medical device and cell therapy company based in Massachusetts and California. Arbios’ portfolio of extracorporeal blood therapies includes the SEPET™ Liver Assist Device, a novel blood purification therapy currently undergoing favorable clinical testing for patients experiencing acute exacerbation of chronic liver disease caused by viral hepatitis B, C or alcoholic cirrhosis, and the HepatAssist™ Cell-Based Liver Support System which combines blood detoxification with liver cell therapy intended to provide replacement of whole liver function for patients with acute and severe acute-on-chronic liver failure. HepatAssist™ has been shown in a randomized Phase II-III clinical trial to enhance survival of acute liver failure patients eligible for liver transplantation. For further information on the Company, access the website at http://www.arbios.com.
This press release contains forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the goals and results of the clinical tests to be conducted by the Company, the future size of markets and therapeutic indications for the Company’s products under development, and the reaction of regulatory authorities regarding the results of past and future clinical trials. These statements represent the judgment of Arbios' management as of this date and are subject to risks and uncertainties that could materially affect the Company. Arbios cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements. Please refer to our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004 for a description of risks that may affect our results or business conditions. The Company does not undertake any obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events except as required by law. SEPET™ and HepatAssist-2™ are trademarks of Arbios Systems, Inc.
